Abstract:Background: Renal Cell Carcinoma (RCC) is the most common type of kidney cancer (85%). 75% of the RCC cases involve conventional clear cell RCC (ccRCC). Approximately, 39% of late-stage patients (stage IV) are treated with chemotherapeutic agents. Phosphatidylinositol-3-kinase (PI3K) and Mitogen-Activated Protein Kinase Kinase (MEK)/extracellular signal-regulated kinase (ERK1/2) pathways are frequently activated in RCC. In addition, atypical PKCs (PKC-ί and PKC ζ) are overexpressed in most cancer cells, and they play a central role in tumor progression and the metastasis of different types of cancers. Our goal is to establish the role of aPKCs in the regulation of multiple key activated pathways in ccRCC. In this study, we also established a novel therapeutic regimen for dual inhibition of key activated pathways. Method: In this study, 786-0 and Caki-1 cells were studied and subjected to cell viability assay, western blot analysis, scratch & wound healing assay, transwell invasion assay, immunofluorescence, immunoprecipitation, flow cytometry, and quantitative real-time polymerase chain reaction. We used combination of PI3K inhibitor- Alpelisib (BYL719) and ICA-1 (a PKC-ι-specific 5-amino-1-2,3-dihydroxy-4-(methylcyclopentyl)-1H-imidazole-4-carboxamide). In addition to drug treatment, small interfering RNA (siRNA) technology was used to further confirm the experimental outcome of the drug treatment. Results: Our results suggest that treatment of ccRCC cells with a combination of ICA-1 (aPKC inhibitor) and BYL719 (PI3K inhibitor) downregulates PKC-ί and causes downstream inhibition of c-Myc. Inhibition of the PKCί also reduces activation of MEK/ERK1/2. It is observed that treatment with ICA-1 disrupts the level of the aPKC-Akt1 association. ICA-1 treatment also shows a reduced level of association between aPKC and c-Myc. The inhibition of aPKCs and downstream effector proteins by combination therapy is more pronounced compared to a single therapy. These effects contribute to reduced cell growth, and eventually, the induction of apoptosis. The decreased level of N-cadherin, p-vimentin, and vimentin and the increased level of E-cadherin confirm reduced malignancy. Conclusion: Therefore, implementing a combination of Alpelisib and a PKC-ι inhibitor is an effective approach to reducing cell proliferation, and invasion that eventually induces apoptosis and may be considered as a potential therapeutic option in ccRCC.

Chaperon‑mediated Autophagy Can Promote Proliferation and Invasion of Renal Carcinoma Cells and Inhibit Apoptosis Through PKM2.

A study of radiosensitizing effect of PKM2 silencing in lung adenocarcinoma cells and xenografts

Chaperone-mediated Autophagy Regulates Apoptosis and the Proliferation of Colon Carcinoma Cells.

HMGCR Inhibition Stabilizes the Glycolytic Enzyme PKM2 to Support the Growth of Renal Cell Carcinoma

RGD-modified Oncolytic Adenovirus-Harboring Shpkm2 Exhibits a Potent Cytotoxic Effect in Pancreatic Cancer Via Autophagy Inhibition and Apoptosis Promotion.

Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma

Tumor-associated M2 macrophages in the immune microenvironment influence the progression of renal clear cell carcinoma by regulating M2 macrophage-associated genes

Crosstalk of renal cell carcinoma cells and tumor-associated macrophages aggravates tumor progression by modulating muscleblind-like protein 2/B-cell lymphoma 2/beclin 1-mediated autophagy

Chaperone-mediated autophagy receptor modulates tumor growth and chemoresistance in non-small cell lung cancer

Novel Specific Pyruvate Kinase M2 Inhibitor, Compound 3h, Induces Apoptosis and Autophagy through Suppressing Akt/mTOR Signaling Pathway in LNCaP Cells

Autophagy Suppresses the Proliferation of Renal Carcinoma Cell.

LAMP2A overexpression in colorectal cancer promotes cell growth and glycolysis via chaperone‑mediated autophagy

PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma

Disruption of Autophagic Flux and Treatment with the PDPK1 Inhibitor GSK2334470 Synergistically Inhibit Renal Cell Carcinoma Pathogenesis

PKM2 Upregulation Promotes Malignancy and Indicates Poor Prognosis for Intrahepatic Cholangiocarcinoma.

Pyruvate Kinase M2 Activates Mtorc1 by Phosphorylating AKT1S1.

Enhanced Expression of PKM2 Associates with the Biological Properties of Cancer Stem Cells from A549 Human Lung Cancer Cells

Dual inhibition of atypical PKC signaling and PI3K/Akt signaling dysregulates c-Myc to induce apoptosis in clear cell Renal Cell Carcinoma

PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment

PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer

Knockdown of ALPK2 Blocks Development and Progression of Renal Cell Carcinoma